Teva Pharmaceutical Industries Ltd (NYSE:TEVA) was the recipient of a large growth in short interest during the month of December. As of December 29th, there was short interest totalling 87,650,494 shares, a growth of 8.4% from the December 15th total of 80,866,638 shares. Based on an average daily trading volume, of 19,333,494 shares, the days-to-cover ratio is presently 4.5 days.

Several institutional investors and hedge funds have recently bought and sold shares of TEVA. Schwab Charles Investment Management Inc. lifted its holdings in shares of Teva Pharmaceutical Industries by 7.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 241,571 shares of the company’s stock valued at $8,025,000 after buying an additional 17,116 shares during the period. State Board of Administration of Florida Retirement System lifted its holdings in shares of Teva Pharmaceutical Industries by 1.5% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 42,611 shares of the company’s stock valued at $1,416,000 after buying an additional 611 shares during the period. Prudential Financial Inc. lifted its holdings in shares of Teva Pharmaceutical Industries by 0.9% in the 2nd quarter. Prudential Financial Inc. now owns 77,973 shares of the company’s stock valued at $2,590,000 after buying an additional 730 shares during the period. Principal Financial Group Inc. raised its holdings in Teva Pharmaceutical Industries by 21.1% during the second quarter. Principal Financial Group Inc. now owns 124,174 shares of the company’s stock worth $4,125,000 after purchasing an additional 21,658 shares during the last quarter. Finally, Fiera Capital Corp raised its holdings in Teva Pharmaceutical Industries by 2.4% during the second quarter. Fiera Capital Corp now owns 188,974 shares of the company’s stock worth $6,278,000 after purchasing an additional 4,463 shares during the last quarter. 51.98% of the stock is owned by institutional investors and hedge funds.

A number of research firms recently issued reports on TEVA. ValuEngine upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Zacks Investment Research raised Teva Pharmaceutical Industries from a “strong sell” rating to a “hold” rating in a research report on Tuesday, January 2nd. Oppenheimer reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 4th. Cantor Fitzgerald set a $18.00 price objective on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Wednesday, January 3rd. Finally, Mizuho raised Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $19.12 to $23.00 in a research report on Tuesday, January 9th. Eight research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. Teva Pharmaceutical Industries has an average rating of “Hold” and an average target price of $21.17.

Shares of Teva Pharmaceutical Industries (NYSE:TEVA) opened at $22.07 on Monday. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 1.20. The company has a market capitalization of $21,400.00, a P/E ratio of -3.76, a PEG ratio of 1.58 and a beta of 0.54. Teva Pharmaceutical Industries has a 1-year low of $10.85 and a 1-year high of $37.94.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Thursday, November 2nd. The company reported $0.95 EPS for the quarter, missing the consensus estimate of $1.03 by ($0.08). Teva Pharmaceutical Industries had a negative net margin of 24.35% and a positive return on equity of 15.70%. sell-side analysts anticipate that Teva Pharmaceutical Industries will post 3.72 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/01/15/teva-pharmaceutical-industries-ltd-teva-short-interest-update.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.